Shield Therapeutics (STX) News Today → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free STX Stock Alerts GBX 1.80 -0.05 (-2.70%) (As of 04:15 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 4:47 AM | americanbankingnews.comShield Therapeutics (LON:STX) Shares Up 16.4%May 9, 2024 | finance.yahoo.comInsider Traders Lose US$91k As Shield Therapeutics DropsMay 3, 2024 | msn.comGalera Therapeutics Implements Stockholder Rights Plan to Shield Investor InterestsMay 2, 2024 | msn.comTurning a tumor's 'shield' into a weapon against itselfApril 10, 2024 | msn.comNeutral Switzerland joins European Sky Shield defence projectApril 1, 2024 | tmcnet.comAmerican Home Shield Offering 40% Off ShieldGold™ For Limited TimeMarch 29, 2024 | msn.comA Real Life Invisibility Shield for Privacy in Public PlacesMarch 11, 2024 | tmcnet.comSeal Shield to Showcase Shyld AI, the World's First Intelligent, Autonomous, UV-C Disinfection System at HIMSS 2024February 23, 2024 | lse.co.ukLONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutesFebruary 22, 2024 | morningstar.comShield Therapeutics PLC STXFebruary 13, 2024 | uk.finance.yahoo.comShield Therapeutics plc (STX.L)January 24, 2024 | finance.yahoo.comShield Therapeutics (LON:STX) shareholders have endured a 89% loss from investing in the stock three years agoDecember 28, 2023 | finance.yahoo.comShield Therapeutics plc (LON:STX) Is Expected To Breakeven In The Near FutureOctober 20, 2023 | proactiveinvestors.comShield Therapeutics to present at NPWH conference this monthOctober 12, 2023 | marketwatch.comShield Therapeutics CFO Hans-Peter Rudolf to Step DownOctober 12, 2023 | proactiveinvestors.comShield Therapeutics launches executive search process as CFO steps downOctober 5, 2023 | finance.yahoo.comShield Therapeutics "couldn't be more pleased" with Viatris collaborationOctober 5, 2023 | finance.yahoo.comShield Therapeutics' pricing will be "key metric" - Proactive Research AnalystOctober 3, 2023 | proactiveinvestors.comShield Therapeutics secures debt facility, retail share offer closes soonSeptember 30, 2023 | finance.yahoo.comShield Therapeutics First Half 2023 Earnings: US$0.025 loss per share (vs US$0.069 loss in 1H 2022)September 29, 2023 | msn.comShield Therapeutics hails progress in Stateside venture as losses narrowSeptember 28, 2023 | marketwatch.comShield Therapeutics Shares Fall After Discounted Equity RaiseSeptember 5, 2023 | finance.yahoo.comPrivate companies who hold 41% of Shield Therapeutics plc (LON:STX) gained 17%, institutions profited as wellJuly 29, 2023 | proactiveinvestors.comShield Therapeutics : First signs of hoped-for Accrufer Rx inflectionJuly 25, 2023 | finanznachrichten.deHardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gatheringJuly 25, 2023 | finance.yahoo.comShield Therapeutics "really starting to fire on all cylinders"July 20, 2023 | marketwatch.comShield Therapeutics Shares Rise as US Prescriptions for Accrufer SoarJuly 20, 2023 | msn.comShield Therapeutics makes waves in US as iron deficiency prescriptions ramp upJuly 20, 2023 | proactiveinvestors.comShield Therapeutics reports 173% Accrufer prescription growthJuly 11, 2023 | msn.comSave $30 on the Nvidia Shield Android TV for Amazon Prime DayJuly 7, 2023 | msn.comNeutral Swiss join Europe's Sky Shield defenceJuly 4, 2023 | barrons.comSwiss Want In On Germany's Sky Shield PlanMay 17, 2023 | uk.movies.yahoo.comHardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptionsMay 4, 2023 | proactiveinvestors.comShield Therapeutics directors urge rejection of mandatory offerMay 2, 2023 | proactiveinvestors.comShield Therapeutics well positioned with "great partnership" - Proactive Research AnalystApril 27, 2023 | proactiveinvestors.comShield Therapeutics ready to go full throttle in the USApril 5, 2023 | proactiveinvestors.comShield Therapeutics appoints chief commercial officer as group readies for US sales offensiveMarch 27, 2023 | finance.yahoo.comLoss-Making Shield Therapeutics plc (LON:STX) Expected To Breakeven In The Medium-TermFebruary 13, 2023 | finance.yahoo.comShield Therapeutics "ended 2022 in a very very productive state"February 13, 2023 | finance.yahoo.comProactive research analyst says Shield Therapeutics "in fast growth mode"February 9, 2023 | benzinga.comPrivacy Shield: The Six Things You Need to Know That Might Affect Your CompanyFebruary 9, 2023 | proactiveinvestors.comShield Therapeutics primed for a strong year as it confirms plans to become self-sufficientFebruary 9, 2023 | proactiveinvestors.comShield Therapeutics shares jump 13%; broker sets punchy price targetJanuary 23, 2023 | markets.businessinsider.comHardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capitalJanuary 13, 2023 | uk.finance.yahoo.comHardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitabilityDecember 14, 2022 | proactiveinvestors.comProactive research analyst on Shield TherapeuticsDecember 14, 2022 | proactiveinvestors.comShield Therapeutics completes fundraiseDecember 13, 2022 | msn.comShield Therapeutics secures £15.1m in raise and seals deal with healthcare companyDecember 13, 2022 | proactiveinvestors.comShield Therapeutics agrees US partnership to promote Accrufer, launches equity fundingOctober 31, 2022 | proactiveinvestors.comShield Therapeutics’ lead product Accrufer expected to gain Korean regulatory approval in 2023 Get Shield Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Email Address This is the best new way to score with AI (Ad)If you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open. Click now for the best way into the newest AI projects STX Media Mentions By Week STX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STX News Sentiment▼0.210.55▲Average Medical News Sentiment STX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STX Articles This Week▼20▲STX Articles Average Week Get Shield Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CHLL News Today MXC News Today VLG News Today SNG News Today TLY News Today ABDX News Today INHC News Today IHC News Today BVX News Today PRM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:STX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDoes this make you sick?Allegiance Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
